AstraZeneca’s MedImmune Specialty Care to present eleven abstracts on influenza, RSV at upcoming annual Pediatric Academic Societies Meeting

Saturday, 3 May 2014

MedImmune Specialty Care division of AstraZeneca (MedImmune Specialty Care) announced today the presentation of 11 abstracts at the 2014 Pediatric Academic Societies (PAS) and Asian Society for Pediatric Research (ASPR) Joint Meeting. These abstracts advance the body of existing data and knowledge around influenza and respiratory syncytial virus (RSV) prevention, highlighting MedImmune Specialty Care’s continued commitment to infectious disease and patient health. The presentations will take place from May 3 – 6, 2014 at the Vancouver Convention Centre in Vancouver, BC, Canada.

MedImmune Specialty Care’s influenza-related abstracts:

  • Live Attenuated Influenza Vaccine (LAIV) Efficacy in Children Vaccinated in Two Successive SeasonsCaspard H, Wu X, Ambrose CS. May 5, 2014, 4:15 PM – 7:30 PM; Session: 3810 – Infectious Diseases; Exhibit Hall C; Board: 221
  • Pediatric Seasonal Influenza Vaccination Coverage Trends (2007-2012) in a Privately Insured PopulationAntonova E, Kern D, Block SL, Caspard H, Tunceli O, Ambrose CS. May 5, 2014, 4:15 PM – 7:30 PM; Session: 3810 – Infectious Diseases; Exhibit Hall C; Board: 223

MedImmune Specialty Care’s RSV-related abstracts:

  • Risk Factors for Outpatient Illness due to Respiratory Viruses in US Preterm Infants: Findings from a Two-Year Prospective Cohort StudyAmbrose CS, Simoes EAF, Anderson EJ, Wu X, Groothuis JR. May 3, 2014, 1:00 PM – 4:00 PM; Session: 1522 – Infectious Diseases; Exhibit Hall C; Board: 327
  • The Underrecognized Burden of RSV Among Infants Presenting to US Emergency DepartmentsAmbrose CS, Wu X, Makari D. May 3, 2014, 1:00 PM – 4:00 PM; Session: 1522 – Infectious Diseases; Exhibit Hall C; Board: 333
  • Burden of Outpatient Illness due to Respiratory Viruses in US Preterm Infants: Findings from a Two-Year Prospective Cohort StudyAmbrose CS, Simoes EAF, Anderson EJ, Wu X, Groothuis JR. May 3, 2014, 1:00 PM – 4:00 PM; Session: 1522 – Infectious Diseases; Exhibit Hall C; Board: 334
  • A Population-Weighted Estimate of Palivizumab Efficacy in Preventing Hospitalizations among US High-Risk ChildrenAmbrose CS, Kumar VR, Chen X. May 3, 2014, 1:00 PM – 4:00 PM; Session: 1522 – Infectious Diseases; Exhibit Hall C; Board: 341
  • Respiratory Syncytial Virus Surveillance, 2007-2013: Results from RSVAlert, an Online U.S. National Hospital-Based Surveillance ProgramAmbrose CS, Kumar VR. May 3, 2014, 1:00 PM – 4:00 PM; Session: 1522 – Infectious Diseases; Exhibit Hall C; Board: 348
  • Care Seeking for RSV Disease in Preterm Infants Born at 32-35 Weeks Gestation: Findings from a Two-Year Cohort StudyAmbrose CS, Wu X, Ryan F, Anderson EJ, Simoes EAF. May 3, 2014, 1:00 PM – 4:00 PM; Session: 1522 – Infectious Diseases; Exhibit Hall C; Board: 350
  • Association between Palivizumab Level and Probability of Respiratory Syncytial Virus Admission to the Pediatric Intensive Care Unit among High-Risk InfantsKumar VR, Ambrose CS, Forbes M, Wu X, Yogev R, Caspard H. May 3, 2014, 1:00 PM – 4:00 PM; Session: 1522 – Infectious Diseases; Exhibit Hall C; Board: 353
  • Receipt of Palivizumab Prior to Discharge from the Birth Hospitalization During RSV Season Among Infants 30 Weeks Gestational Age in the United States. Kumar VR, LaGamma EF, Wadhawan R, Ye S, Sifakis F, Ambrose CS. May 3, 2014, 1:00 PM – 4:00 PM; Session: 1546 – Neonatology; Exhibit Hall C; Board: 720
  • How Many Preterm Infants are Born in the United States Each Year? Ambrose CS, Rizzo C, Caspard H. May 6, 2014, 7:00 AM – 11:00 AM; Session: 4137 – General Pediatrics & Preventive Pediatrics; Exhibit Hall C; Board: 510

Additional information about the 2014 PAS/ASPR conference can be found at: http://www.pas-meeting.org/

NOTES TO EDITORS

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit www.astrazeneca-us.com.

About MedImmune Specialty Care

MedImmune Specialty Care Division of AstraZeneca is a patient-focused, biopharmaceutical business unit responsible for the commercialization of small molecule and biologic prescription medicines for AstraZeneca. Within the U.S., MedImmune Specialty Care provides commercial support and insights for in-line marketed products addressing respiratory, inflammation and autoimmunity, oncology, infection and vaccines. Headquarters are located in Gaithersburg, Maryland.

CONTACTS

Media Inquiries  
   
Michele Meixell (AstraZeneca US) +1 302 885 2677